AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04532476 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser therapy
Description: Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators.
Study NCT04267341 — intervention group
Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
Study NCT04267341 — intervention group
Intervention type: OTHER
Intervention: 10 Meter Walk Test
Description: 10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
Study NCT04267341 — intervention group
Intervention type: OTHER
Intervention: Purdue Pegboard Test
Description: Purdue Pegboard test evaluates the fine manuel dexterity
Study NCT02241369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3106, INO-9012
Study NCT01017003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine tablets
Description: 0.6mg colchicine tablet
Study NCT01017003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine tablets
Description: 0.6mg q12 hours for 10 days
Study NCT03426956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Ingestion of glucose (50 g) dissolved in 200 ml water.
Study NCT03426956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose + Canagliflozin
Description: Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
Study NCT00974246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair diskus
Description: Advair diskus 50/250 1 inhalation bid for 16 weeks
Study NCT04615754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hyperketonemia - use of ketone (3-OHB) infusion
Description: The effect of intravenous ketone supplement
Study NCT04615754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo - use of saline infusion
Description: Saline is infused as an comparator
Study NCT04451577 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, analysis of biological samples
Study NCT00058812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV specific T cells
Description: One injection of 2x10\^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
Study NCT04298775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia with morphine
Study NCT04298775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia without morphine + peripheral nerve block
Study NCT02069470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing Medical Education
Description: 3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
Study NCT03166566 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laminar drainage implant surgery.
Description: A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
Study NCT02718742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02718742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT02718742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00344721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid supplement
Description: Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
Study NCT00344721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
Study NCT03913052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Viscosupplement Application
Description: Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
Study NCT01301443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subretinally injected RetinoStat
Description: Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
Study NCT01911442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 20 mg daily
Description: Lurasidone 20 mg once daily
Study NCT01911442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 60 mg once daily
Study NCT01911442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00808236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RhinoChill
Description: Nasal catheters are placed and cooling is begun during the resuscitation attempt
Study NCT00808236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Advanced cardiac life support according to American Heart Association \& European Resuscitation Council 2005 Guidelines
Study NCT00362934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate / simvastatin
Description: Combination of fenofibrate and simvastatin 20 mg and 40 mg
Study NCT00362934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 mg and 20mg
Study NCT02153528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: double rimfampicin
Description: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
Study NCT02153528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard TB treatment
Description: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Study NCT01908270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study NCT01908270 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT01908270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT02336659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin 9-39
Description: Exendin 9-39 is a specific GLP-1 receptor antagonist
Study NCT02336659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: DPP-4 Inhibition
Study NCT02336659 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00141024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1043
Description: Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials.
Study NCT00141024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1090
Description: DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
Study NCT03853681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: additional blood sampling
Description: additional blood sampling
Study NCT03436459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device
Study NCT03436459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
Study NCT01576770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lidocaine/tetracaine transdermal patch (NDC 43469-864-01)
Description: 70 mg lidocaine / 70 mg tetracaine
Study NCT01576770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gebauer's Ethyl Chloride
Description: Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
Study NCT02221531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin Short-infusion
Description: Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
Study NCT02221531 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carbetocin Bolus application
Description: Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
Study NCT02386280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Change of Parenting Styles
Study NCT02386280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psicoeducation
Study NCT02386280 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psicoeducation
Study NCT04899271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: 400 mg b.i.d. for 13 cycles of 14 days on/14 days off
Study NCT04899271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally with the same scheme of administration of LDX to preserve blinding
Study NCT00455689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women.
Study NCT06078423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program
Description: Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
Study NCT06078423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program
Description: Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
Study NCT06078423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program
Description: Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
Study NCT06078423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program
Description: Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
Study NCT02534688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Study NCT02534688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA
Study NCT04688775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab - concentrate for solution for infusion, intravenously
Study NCT04688775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
Study NCT02847195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pupillometry
Description: This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
Study NCT01102075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
Study NCT01102075 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture procedure
Description: We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
Study NCT03675035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: Reduction of the gastro-jejunal anastomosis through sutures
Study NCT03216096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
Description: Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
Study NCT03495258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clarion Evolve Laser Vaporization System
Study NCT03495258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Olympus TURis Plasma Vaporization
Study NCT03186690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Study NCT03186690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Study NCT01565915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perlane-L
Description: Perlane-L Injection in the midface
Study NCT01565915 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-treatment
Description: Non-treatment Arm
Study NCT00793260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Support
Description: The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness.
Study NCT00793260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual-Support
Description: Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
Study NCT04101565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text4Father
Description: Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
Study NCT02354222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Canagliflozin
Study NCT02354222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Study NCT02354222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Study NCT02354222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02996188 — intervention group
Intervention type: PROCEDURE
Intervention: routine therapeutic paracentesis
Study NCT02359630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EasyTube
Description: Insertion for ventilation
Study NCT02359630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyTube
Description: Insertion for ventilation
Study NCT02359630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Insertion for ventilation
Study NCT02359630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Description: Insertion for ventilation
Study NCT03803072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time restricted eating (TRE)
Description: Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
Study NCT00456105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician
Description: See Detailed Description.
Study NCT00456105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team
Description: See detailed description.
Study NCT00456105 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Subjects without diabetes will have their blood glucose levels monitored while in the hospital
Description: See detailed description.
Study NCT04060420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive sexual and reproductive health services
Description: The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
Study NCT03154814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
Study NCT03154814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: conventional CPB was applied without ulinastatin treatment
Study NCT03509142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
Description: Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Study NCT01225731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose
Study NCT01225731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration of Placebo
Study NCT04586543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: 10 mg selegiline tablet per day